Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 5/20 | 0.39 |
| ▸ | KIF11 | P52732 | 7/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29455263 | 0.89 | CASP1 (0.37) | SMN1; SMN2CASP1KIF11CYP3A4TGM2 | |
| SCHEMBL29455275 | 0.88 | CASP1 (0.41) | CASP1KIF11CYP3A4TGM2ALDH1A1 | |
| SCHEMBL29455255 | 0.78 | L3MBTL1 (0.37) | SMN1; SMN2CASP1KIF11NPC1RAB9A | |
| SCHEMBL29455257 | 0.77 | L3MBTL1 (0.36) | CASP1KIF11NPC1RAB9AFAAH | |
| SCHEMBL5666943 | 0.75 | NPC1 (0.48) | SMN1; SMN2KIF11CYP3A4TGM2ALDH1A1 | |
| SCHEMBL19265866 | 0.73 | IDO1 (0.54) | SMN1; SMN2KIF11NPC1RAB9A | |
| SCHEMBL31370698 | 0.72 | CASP1 (0.49) | CASP1KIF11ALDH1A1 | |
| SCHEMBL13055388 | 0.71 | MAPT (0.42) | CASP1CYP3A4TSHR | |
| SCHEMBL29032309 | 0.71 | SMN1; SMN2 (0.44) | SMN1; SMN2KIF11ALDH1A1NPC1RAB9A | |
| SCHEMBL4589970 | 0.70 | CYP3A4 (0.44) | SMN1; SMN2CASP1CYP3A4ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA GMBH (DE) | 2024-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041897-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | SMN1; SMN2 3213/4885CASP1 1857/4885KIF11 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.